IBO 最新10-Q变化
将 IBO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-12 与上一份 10-Q · 2025-11-07
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +37 | −52 | ~17 | 38 |
| 控制与程序 | 文字有新增/删除 | +37 | −52 | ~17 | 38 |
| 法律诉讼 | 文字有新增/删除 | +37 | −52 | ~17 | 38 |
| 风险因素 | 文字有新增/删除 | +37 | −52 | ~17 | 38 |
| 其他信息 | 文字有新增/删除 | +37 | −52 | ~16 | 38 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-12
Stock-based payment for professional services received - 29,000
Net cash (used) provided by investing activities (1,000) 1,000
DSS Biomedical International, Inc. Nevada April 9, 2021 100% 100%
As of March 31, 2026, and December 31, 2025, the aggregate noncontrolling interest was equity of $3,247,000 and $3,244,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
The Company identified and corrected immaterial classification errors in our previously reported Consolidated balance sheet as of December 31, 2025 and 2024. The correction of this error resulted in a reclassified $298,000 from additional paid-in capital to noncontrolling interests within equity to …
相对上期删除的文字 · 来源:10-Q · 2025-11-07
Issuance of shares for professional services rendered 190,000
Issuances of common stock, net of issuance costs - 3,726,000
As of September 30, 2025, and December 31, 2024, the aggregate noncontrolling interest was equity of $2,956,000 and $2,978,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
Costs in the amount of $82,000 associated with research and development have been reclassed from Professional fees to Research and development expenses for the three months ended September 30, 2024 and $336,000 for the nine months ended September 30, 2024 on the accompanying Condensed Consolidated s…
The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no cash equivalents as of September 30, 2025 and December 31, 2024.
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-05-12
Stock-based payment for professional services received - 29,000
Net cash (used) provided by investing activities (1,000) 1,000
DSS Biomedical International, Inc. Nevada April 9, 2021 100% 100%
As of March 31, 2026, and December 31, 2025, the aggregate noncontrolling interest was equity of $3,247,000 and $3,244,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
The Company identified and corrected immaterial classification errors in our previously reported Consolidated balance sheet as of December 31, 2025 and 2024. The correction of this error resulted in a reclassified $298,000 from additional paid-in capital to noncontrolling interests within equity to …
相对上期删除的文字 · 来源:10-Q · 2025-11-07
Issuance of shares for professional services rendered 190,000
Issuances of common stock, net of issuance costs - 3,726,000
As of September 30, 2025, and December 31, 2024, the aggregate noncontrolling interest was equity of $2,956,000 and $2,978,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
Costs in the amount of $82,000 associated with research and development have been reclassed from Professional fees to Research and development expenses for the three months ended September 30, 2024 and $336,000 for the nine months ended September 30, 2024 on the accompanying Condensed Consolidated s…
The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no cash equivalents as of September 30, 2025 and December 31, 2024.
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-05-12
Stock-based payment for professional services received - 29,000
Net cash (used) provided by investing activities (1,000) 1,000
DSS Biomedical International, Inc. Nevada April 9, 2021 100% 100%
As of March 31, 2026, and December 31, 2025, the aggregate noncontrolling interest was equity of $3,247,000 and $3,244,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
The Company identified and corrected immaterial classification errors in our previously reported Consolidated balance sheet as of December 31, 2025 and 2024. The correction of this error resulted in a reclassified $298,000 from additional paid-in capital to noncontrolling interests within equity to …
相对上期删除的文字 · 来源:10-Q · 2025-11-07
Issuance of shares for professional services rendered 190,000
Issuances of common stock, net of issuance costs - 3,726,000
As of September 30, 2025, and December 31, 2024, the aggregate noncontrolling interest was equity of $2,956,000 and $2,978,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
Costs in the amount of $82,000 associated with research and development have been reclassed from Professional fees to Research and development expenses for the three months ended September 30, 2024 and $336,000 for the nine months ended September 30, 2024 on the accompanying Condensed Consolidated s…
The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no cash equivalents as of September 30, 2025 and December 31, 2024.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-05-12
Stock-based payment for professional services received - 29,000
Net cash (used) provided by investing activities (1,000) 1,000
DSS Biomedical International, Inc. Nevada April 9, 2021 100% 100%
As of March 31, 2026, and December 31, 2025, the aggregate noncontrolling interest was equity of $3,247,000 and $3,244,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
The Company identified and corrected immaterial classification errors in our previously reported Consolidated balance sheet as of December 31, 2025 and 2024. The correction of this error resulted in a reclassified $298,000 from additional paid-in capital to noncontrolling interests within equity to …
相对上期删除的文字 · 来源:10-Q · 2025-11-07
Issuance of shares for professional services rendered 190,000
Issuances of common stock, net of issuance costs - 3,726,000
As of September 30, 2025, and December 31, 2024, the aggregate noncontrolling interest was equity of $2,956,000 and $2,978,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
Costs in the amount of $82,000 associated with research and development have been reclassed from Professional fees to Research and development expenses for the three months ended September 30, 2024 and $336,000 for the nine months ended September 30, 2024 on the accompanying Condensed Consolidated s…
The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no cash equivalents as of September 30, 2025 and December 31, 2024.
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-05-12
Stock-based payment for professional services received - 29,000
Net cash (used) provided by investing activities (1,000) 1,000
DSS Biomedical International, Inc. Nevada April 9, 2021 100% 100%
As of March 31, 2026, and December 31, 2025, the aggregate noncontrolling interest was equity of $3,247,000 and $3,244,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
The Company identified and corrected immaterial classification errors in our previously reported Consolidated balance sheet as of December 31, 2025 and 2024. The correction of this error resulted in a reclassified $298,000 from additional paid-in capital to noncontrolling interests within equity to …
相对上期删除的文字 · 来源:10-Q · 2025-11-07
Issuance of shares for professional services rendered 190,000
Issuances of common stock, net of issuance costs - 3,726,000
As of September 30, 2025, and December 31, 2024, the aggregate noncontrolling interest was equity of $2,956,000 and $2,978,000, respectively, which are separately disclosed on the Condensed Consolidated Balance Sheets.
Costs in the amount of $82,000 associated with research and development have been reclassed from Professional fees to Research and development expenses for the three months ended September 30, 2024 and $336,000 for the nine months ended September 30, 2024 on the accompanying Condensed Consolidated s…
The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no cash equivalents as of September 30, 2025 and December 31, 2024.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议